Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum

Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with ste...

Full description

Saved in:
Bibliographic Details
Published inAnnals of dermatology Vol. 35; no. s1; pp. 107 - 111
Main Authors Hae Chan Lee, Yiyoung Kwon, Eun Sil Kim, Soomin Ahn, Yon Ho Choe, Mi Jin Kim
Format Journal Article
LanguageKorean
Published 대한피부과학회 31.05.2023
Subjects
Biological therapy
Infliximab
Pyoderma gangrenosum
Ulcerative colitis
Vedolizumab
Online AccessGet full text

Cover

More Information
Summary:Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
Bibliography:The Korean Dermatological Association
ISSN:1013-9087
2005-3894